Literature DB >> 33769959

Selective vs non-selective alpha-blockade prior to adrenalectomy for pheochromocytoma: systematic review and meta-analysis.

Karolina Zawadzka1, Krzysztof Więckowski1, Piotr Małczak1,2, Michał Wysocki1,2, Piotr Major1,2, Michał Pędziwiatr1,2, Magdalena Pisarska-Adamczyk1,2.   

Abstract

OBJECTIVE: Alpha-adrenergic blockade is currently the first choice of preoperative treatment in patients with functional pheochromocytoma and sympathetic paraganglioma. Nevertheless, there is no consensus whether selective or non-selective alpha-blockade is superior for preventing both perioperative hemodynamic instability and complications.
DESIGN: Our study aimed to compare selective and non-selective alpha-blockade through a systematic review with meta-analysis.
METHODS: MEDLINE, Embase, Web of Science and Cochrane Library were searched for eligible studies. Randomized and observational studies comparing selective and non-selective alpha-blockade in pheochromocytoma and sympathetic paraganglioma surgery in adults were included. Data on perioperative hemodynamic parameters and postoperative outcomes were extracted.
RESULTS: Eleven studies with 1344 patients were enrolled. Patients receiving selective alpha-blockade had higher maximum intraoperative systolic blood pressure (WMD: 12.14 mmHg, 95% CI: 6.06-18.21, P < 0.0001) compared to those treated with non-selective alpha-blockade. Additionally, in the group pretreated with selective alpha-blockers, intraoperative vasodilators were used more frequently (OR: 2.46, 95% CI 1.44-4.20, P = 0.001). Patients treated with selective alpha-blockers had lower minimum intraoperative systolic blood pressure (WMD: -2.03 mmHg, 95% CI: -4.06 to -0.01, P = 0.05) and shorter length of hospital stay (WMD: -0.58 days, 95% CI: -1.12 to -0.04, P = 0.04). Operative time, overall morbidity and mortality did not differ between the groups.
CONCLUSIONS: This meta-analysis shows non-selective alpha-blockade was more effective in preventing intraoperative blood pressure fluctuations while maintaining comparable risk of both intraoperative and postoperative hypotension and overall morbidity.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33769959     DOI: 10.1530/EJE-20-1301

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Role of Preoperative Blockade in Pheochromocytoma-Paraganglioma: A Clinician's Perspective.

Authors:  Manjiri P Karlekar; Saba S Memon; Tushar R Bandgar
Journal:  Indian J Endocrinol Metab       Date:  2022-04-27

Review 2.  Perioperative Management of Pheochromocytomas and Sympathetic Paragangliomas.

Authors:  Gustavo F C Fagundes; Madson Q Almeida
Journal:  J Endocr Soc       Date:  2022-01-14

3.  Adrenal bleeding due to pheochromocytoma - A call for algorithm.

Authors:  Ewelina Rzepka; Joanna Kokoszka; Anna Grochowska; Magdalena Ulatowska-Białas; Martyna Lech; Marta Opalińska; Elwira Przybylik-Mazurek; Aleksandra Gilis-Januszewska; Alicja Hubalewska-Dydejczyk
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-05       Impact factor: 6.055

4.  Surgical treatment of large pheochromocytoma (>6 cm): A 10-year single-center experience.

Authors:  Liang Zhang; Danlei Chen; Yingxian Pang; Xiao Guan; Xiaowen Xu; Cikui Wang; Qiao Xiao; Longfei Liu
Journal:  Asian J Urol       Date:  2022-06-20

Review 5.  Management of Patients with Treatment of Pheochromocytoma: A Critical Appraisal.

Authors:  Florence Bihain; Claire Nomine-Criqui; Philippe Guerci; Stephane Gasman; Marc Klein; Laurent Brunaud
Journal:  Cancers (Basel)       Date:  2022-08-09       Impact factor: 6.575

6.  Surgical outcomes in the pheochromocytoma surgery. Results from the PHEO-RISK STUDY.

Authors:  Marta Araujo-Castro; Rogelio García Centero; María-Carmen López-García; Cristina Álvarez Escolá; María Calatayud Gutiérrez; Concepción Blanco Carrera; Paz De Miguel Novoa; Nuria Valdés Gallego; Felicia A Hanzu; Paola Gracia Gimeno; Mariana Tomé Fernández-Ladreda; Juan Carlos Percovich Hualpa; Mireia Mora Porta; Javier Lorca Álvaro; Héctor Pian; Ignacio Ruz Caracuel; Alfonso Sanjuanbenito Dehesa; Victoria Gómez Dos Santos; Ana Serrano Romero; Cristina Lamas Oliveira
Journal:  Endocrine       Date:  2021-08-09       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.